Compare Crispr Therapeutics AG (CRSP) vs Lamb Weston Holdings Inc (LW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Lamb Weston Holdings Inc — how do they compare? Crispr Therapeutics AG trades at $54.25 (market cap $5.23B), while Lamb Weston Holdings Inc trades at $53.21 (market cap $7.23B). The key difference: Lamb Weston Holdings Inc is the larger of the two by market cap, and Lamb Weston Holdings Inc pays a 2.89% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | LW | |
|---|---|---|
Market Cap | $5.23B | $7.23B |
Sector | Health | Consumer Staples |
52-Week High | $76.78 | $66.57 |
52-Week Low | $44.34 | $38.48 |
Enterprise Value | $3.65B | $11.10B |
Dividend Yield | — | 2.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.83, up 0.6% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a Q2 2026 EPS beat with a loss of $0.94 versus an expected $1.19 loss, driven by surging CASGEVY sales. However, financials show deep losses, with a net income margin of -4,101.26% in 2025 and negative operating cash flow, though financing activities provided liquidity.
The outlook is mixed: strong analyst consensus (57.9% buy ratings) and a $82.67 price target reflect optimism around CASGEVY growth and pipeline catalysts, but high valuation (P/S of 466.05) and persistent cash burn pose significant risks. Investment appeal hinges on successful clinical advancements and path to profitability.
Lamb Weston (LW) trades at $53.04, up 2.37% today, near its consensus price target of $53.86. The stock shows a bullish technical trend with consistent earnings beats in recent quarters, including Q2 2026 EPS of $0.87 versus $0.626 expected. Revenue reached $6.45 billion in 2025, though net income margin declined to 4.39%. Analyst sentiment is mixed with 31.58% buy ratings, while institutional investors like Dimensional Fund Advisors increased holdings by 28.1% in Q1 2026 (SEC filing, 2026-07-29).
The outlook is cautiously optimistic given operational improvements and cost savings, but risks include international demand pressures and elevated costs. The stock offers a 3.1% dividend yield, with fiscal 2027 guidance projecting 1%-2% sales growth. Further upside depends on sustaining North American volume growth and margin stabilization amid macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Lamb Weston Holdings Inc
Lamb Weston is the world's second-largest producer of branded and private-label frozen potato products, such as French fries, sweet potato fries, tater tots, diced potatoes, mashed potatoes, hash browns, and chips. The company also has a small appetizer business that produces onion rings, mozzarella sticks, and cheese curds. Including joint ventures, 63% of fiscal 2022 revenue was U.S.-based, with the remainder stemming from Europe, Canada, Japan, China, Korea, Mexico, and several other countries. Lamb Weston's customer mix is estimated 58% quick-serve restaurants, 19% full-service restaurants, 8% other food services (hotels, commercial cafeterias, arenas, schools), and 16% retail. Lamb Weston became an independent company in 2016 when it was spun off from Conagra.
Read more on LW →
